ClinicalTrials.gg
CompletedNCT02094937Updated May 25, 2017Results posted

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

A Phase 3 interventional study of Fluticasone Furoate/Vilanterol and Fluticasone Furoate 100 mcg in Asthma, sponsored by GlaxoSmithKline. Completed at 33 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-25.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
11th of 40
430 · median 102
Started
2014
the only one that year
Phase 3
14 of 40
none open now
Registered
26th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 11th largest by enrollment, is the only one that started in 2014, is one of 14 in phase 3, and was the 26th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

The primary aim of this study is to clarify the position of FF and FF/Vilanterol (VI) 100/25 micrograms (mcg) compared with existing therapies by assessing FF dosage equivalent to low to middle-dose inhaled corticosteroids (ICS). The study is divided into Run-in period, Period 1 (open-label treatment), Period 2 (double blind treatment) and Follow-up. Subjects with well controlled asthma after completing a run-in period of 4 weeks will be switched from middle-dose ICS/long acting beta 2 agonist (LABA) equivalent dose to once-daily FF/VI 100/25 mcg for an 8 weeks treatment period (Period 1). After this, subjects will be randomized in a 1:1:1 ratio to receive either FP 250 mcg twice daily, FP 100 mcg twice daily or FF 100 mcg once daily in a 12 week double blind treatment period (Period 2). There will be a 1 week Follow-up Period following completion of the double-blind treatment period, or early withdrawal from the study. Overall , the total duration of subject's participation in the study will be for 25 weeks. RELVAR is a registered trademark of the GSK group of companies.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • fluticasone propionate
  • step-down regimen
  • well-controlled subjects
  • adults
  • switching regimen
  • asthma
  • fluticasone furoate
  • fluticasone furoate/Vilanterol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : Subjects must give their signed and dated written informed consent to participate.
  • Type of Subject: Outpatients 18 years of age or older at Visit 1. Subjects must have a diagnosis of asthma as defined by the National Institutes of Health at least 1 year prior to Visit 1.
  • Gender: Male or Eligible Female, defined as non- or childbearing potential using an acceptable method of consistently and correctly, as defined by the following: Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject; Oral contraceptive (either combined estrogen/progestin); Any intrauterine device (IUD) with a documented failure rate of less than 1% per year; Double barrier method - spermacide plus a mechanical barrier (e.g., spermacide plus a male condom or a spermacide and female diaphragm); Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse throughout the clinical trial and for a period after the trial to account for elimination of the drug (minimum of six days); Female subjects should not be enrolled if they are pregnant, lactating or plan to become pregnant during the time of study participation. A serum pregnancy test is required for females of childbearing potential at the initial screening visit (Visit 1) and Visit 11 or Early Withdrawal. In addition a urine pregnancy test will be performed on all females of childbearing potential at Visit 2, Visit 5 and Visit 12.
  • Severity of Disease: A best pre-bronchodilator of >=80% of the predicted normal value at the screening visit (Visit 1). Predicted values will be based upon National Health and Nutrition Examination Survey (NHANES) III. As subjects are Asian, the Asian adjustment will be used.
  • Stable Asthma: Subjects must have stable asthma, as judged by the Investigator. This includes no change in asthma medication for at least 8 weeks prior to Visit 1 and an ACT score of >=20 at Visit 1.
  • Current Anti-Asthma Therapy: All subjects must be using the middle-dose ICS/LABA which is equivalent to twice-daily combination of fluticasone propionate and salmeterol 250 mcg for at least 12 weeks prior to the registration visit. In addition, the prescription of the middle-dose ICS/LABA shouldn't be changed at least 8 weeks prior to Visit 1.
  • Short-Acting Beta2-Agonists (SABA): All subjects must be able to use salbutamol aerosol inhaler which will be provided as a rescue medication at Visit 1 during the study as needed. Subjects must be able to avoid using salbutamol for at least 6 hours prior to study visits.
  • 12-lead (ECG): Evidence of significant normality in the 12-lead ECG performed at Visit 1, as judged by the investigator Selected specific ECG findings that are not considered to be significant and will not exclude the subject from study participation include, but are not limited to, the following: T interval corrected for heart rate () \<450 milliseconds (msec) or QTc \<480 msec for patients with bundle branch block. The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), machine overread. The QTc should be based on single or averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period. If there are any abnormalities including but not limited to a T interval for heart rate (QT) prolonged, confirm with two additional ECGs taken.

Other inclusion criteria at Visit 2 and Visit 5:

  • Subjects whose asthma meets the criterion of "well-controlled" (as defined in the protocol), and in the Investigators judgement it is acceptable for subject to "switch (Visit 2)" and "step-down (Visit 5)" in one week prior to Visit 2 or Visit 5.
  • Compliance rate of the middle-dose ICS/LABA which is equivalent to twice-daily combination of fluticasone propionate and salmeterol 250 mcg (Visit1- Visit 2) and FF/VI 100/25 mcg (Visit 2 - Visit5) should be achieved >=80%
  • Compliance with completion of both morning and evening eDairy data fulfils >=5days in one week prior to Visit 2 and Visit 5.

Exclusion criteria

Exclusion Criteria:

  • History of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 10 years.
  • Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 8 weeks of Visit 1 and led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Asthma Exacerbation: Any asthma exacerbation requiring systemic or injection within 12 weeks of Visit 1 or that resulted in overnight hospitalization requiring additional treatment for asthma within 6 months prior to Visit 1.
  • Concurrent Respiratory Disease: A subject must not have current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, , or other respiratory abnormalities other than asthma.
  • Other Concurrent Diseases/Abnormalities: A subject must not have any , uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study. The list of additional excluded conditions/diseases includes, but is not limited to the following: congestive heart failure, known aortic aneurysm, clinically significant coronary heart disease, clinically significant cardiac arrhythmia, stroke within 3 months of Visit 1, uncontrolled hypertension (two or more measurements with systolic BP >160 millimeters of mercury (mmHg), or diastolic BP >100mmHg), recent or poorly controlled peptic ulcer, haematologic, hepatic, or renal disease, immunologic compromise, current (history of malignancy is acceptable only if subject has been in remission for one year prior to Visit 1 (remission = no current evidence of malignancy and no treatment for the malignancy in the 12 months prior to Visit 1)), tuberculosis (current or untreated) [Subjects with a history of tuberculosis infection who have completed an appropriate course of antituberculous treatment may be suitable for study entry provided that there is no clinical suspicion of active or recurrent disease], Cushing's disease, Addison's disease, uncontrolled diabetes mellitus, uncontrolled thyroid disorder, recent history of drug or alcohol abuse
  • Oropharyngeal Examination: A subject will not be eligible for the run-in if he/she has clinical visual evidence of candidiasis at Visit 1.
  • Medications: A subject must not have used any investigational drug within 30 days prior to Visit 1 or within five half-lives (t1/2) of the prior investigational study (whichever is longer of the two).
  • Allergies: Drug Allergy: Any adverse reaction including immediate or delayed to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the investigational product (i.e., lactose or magnesium stearate); Milk Protein Allergy: History of severe milk protein allergy.
  • Concomitant Medication: Administration of prescription or over the counter medication that would significantly affect the course of asthma, or interact with study drug, such as: anticonvulsants (barbiturates, hydantoins, carbamazepine); polycyclic antidepressants; beta-adrenergic blocking agents; phenothiazines and monoamine oxidase (MAO) inhibitors; Medications: A subject must not be using or require use of immunosuppressive medications during the study.

Note: Immunotherapy for the treatment of allergies is allowed during the study provided it was initiated at least 4 weeks prior to Visit 1 and subjects remain in the maintenance phase for the duration of the study; Cytochrome P450 3A4 () inhibitors: Subjects who have received a potent CYP3A4 inhibitor within 4 weeks of Visit 1 (e.g.,Clarithromycin, atazanavir, indinavir, itraconazole, ketoconazole, nefazadone, nelfinavir; ritonavir; saquinavir; telithromycin, troleandomycin, voriconazole, mibefradil, cyclosporine, etc).

  • Compliance: A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, disease, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol, including visit schedule and completion of eDiaries and a paper medical conditions diary.
  • Tobacco Use: Current smoker or a smoking history of 10 pack years (e.g., 20 cigarettes/day for 10 years). A subject may not have used inhaled tobacco products within the past 3 months (i.e., cigarettes, cigars or pipe tobacco).
  • Affiliation with Investigator's Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.

Other exclusion criteria at Visit 2 and Visit 5:

  • Evidence of clinically significant abnormal laboratory tests during Visit 1which are still abnormal upon repeat analysis and are not believed to be due to disease(s) present. Each Investigator will use his/her own discretion in determining the clinical significance of the abnormality.
  • Changes in asthma medication (excluding salbutamol inhalation aerosol provided at Visit 1).
  • Occurrence of a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear during the run-in and the open-label treatment period that led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Any asthma exacerbation requiring systemic corticosteroids or injection or that resulted in overnight hospitalization requiring additional treatment for asthma. Clinical visual evidence of oral candidiasis at Visit 2 and Visit 5.
  • Positive urine pregnancy test for all females of at Visit 2 and Visit 5
  • Subjects that the investigator decides that it is impossible for subject to do "switch (Visit 2)" and "step-down (Visit 5)".
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
430 participants (actual)

Study arms

  • Experimental
    Arm 1 FF/VI 100/25 mcg

    Subjects will receive Fluticasone Furoate/Vilanterol 100/25 mcg once-daily via a dry powder inhaler for 8 weeks in the open-label treatment period.

    Drug: Fluticasone Furoate/Vilanterol

  • Experimental
    Arm 2 FF 100 mcg

    Subjects will receive Fluticasone Propionate matching placebo twice-daily (morning and evening) and Fluticasone Furoate 100 mcg once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period

    Drug: Fluticasone Furoate 100 mcg · Drug: Fluticasone Propionate Placebo

  • Experimental
    Arm 3 FP 250 mcg

    Subjects will receive Fluticasone Propionate 250 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period

    Drug: Fluticasone Propionate 250 mcg · Drug: Fluticasone Furoate Placebo

  • Experimental
    Arm 4 FP 100 mcg

    Subjects will receive Fluticasone Propionate 100 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period

    Drug: Fluticasone Propionate 100 mcg · Drug: Fluticasone Furoate Placebo

Interventions

  • DrugFluticasone Furoate/Vilanterol

    Drug pages: Fluticasone furoate · Vilanterol

    FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler

  • FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler

  • FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler

  • FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler

  • DrugFluticasone Furoate Placebo

    Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler

  • DrugFluticasone Propionate Placebo

    Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler

06

What researchers measure

Primary outcomes

  1. Percentage of Participants (Par) Withdrawn From the Study Due to "Poorly-controlled Asthma" During Period 2

    Asthma symptom scores (SS) were recorded by par using ratings 0 (no symptoms) to 5-symptoms so severe that par could not perform normal activity \[morning\] or to 4-symptoms so severe that par could not sleep at all \[nightly\]. Withdrawal due to poorly-controlled(WPC) (required step-up therapy) asthma was defined as asthma worsening/exacerbation or ≧3 per week of : day symptoms on ≧ 2 days, rescue use on ≧2 days, morning PEF \<80 % of best effort on ≧ 1 day, night symptoms on ≧1 or more day, a best pre-bronchodilator forced expiratory volume in 1s (FEV1) \< 80% at clinic . Percentage of par WPC asthma at visit 6, 7, 9 and 11 (Week 10, 12, 16 and 20 respectively) were reported. Cox Proportional Hazards Model was used with covariates of Baseline FEV1, gender, age and treatment group. Analysis was descriptive only, no p -values calculated, treatment differences and associated 95% CI were produced.

    Time frame: From Week 9 to Week 20

  2. Percentage of Participants With 'Well-controlled Asthma' at the End of Period 2

    Asthma symptom scores(SS) were recorded by par using ratings 0 (no symptoms) to 5-symptoms so severe that par could not perform normal activity\[morning\] or to 4-symptoms so severe that par could not sleep at all\[nightly\]. "Well-controlled asthma" was defined as having no exacerbation/asthma worsening, no night-time symptoms, a best pre-bronchodilator forced expiratory volume in 1 second ≥80% at clinic, and ≥2 per week of: daytime symptoms on ≤1 day, rescue use on ≤1 day, or morning peak expiratory flow ≥80% of the best effort value. "Well-controlled asthma" at the end of period 2 was assessed in the week prior to Visit 11 (Week 20). Percentage of participants were calculated as the number of participants with "well-controlled asthma" divided by total number participants excluding withdrawals prior to visit 11 (end of period 2) other than asthma worsening/exacerbation. A Logistic Regression Model was used with covariates of Baseline FEV1, gender, age and treatment group.

    Time frame: Week 20

Secondary outcomes

  1. Least Squares Mean Change From Baseline in Clinic Visit Trough FEV1 at the End of Period 2

    FEV measures amount of air a person can exhale during a forced breath. The amount of air exhaled in one second of the forced breath is FEV1. Trough FEV1 was measured between 3pm and 11pm excluding Visit 1. Highest value from the three acceptable measurements were recorded. Change from Baseline was calculated as adjusted mean FEV1 value during Period 2 minus Baseline. The Baseline value was the predose value at the randomization (Visit 5: Week 8). Analysis of covariance (ANCOVA) Model was used with covariates of baseline FEV1, gender, age and treatment group. The adjusted mean from this model is presented \[least square mean (LSM)\].

    Time frame: Week 20

  2. Least Squares Mean Change From Baseline in Daily Morning (AM) and Evening (PM) PEF Averaged During Period 2

    Peak expiratory flow is a person's maximum speed of expiration, as measured with a peak flow meter which determines person's ability to breathe out air. PEF was measured each morning and evening prior to study medication or any rescue salbutamol inhalation aerosol use, using an electronic peak flow meter. Mean change from Baseline was calculated as PEF value averaged during Period 2 (Week 9 to Week 20) minus Baseline. Data is presented separately for morning(AM) and evening(PM) assessments. The Baseline value was the mean of the daily values in one week prior to randomization (Visit 5: Week 8) separately for morning and evening. Adjusted mean change from baseline is presented \[least square mean (LSM)\].

    Time frame: From Week 9 to Week 20

  3. Least Squares Mean Change From Baseline in the Percentage of Symptom Free 24 Hour Periods During Period 2

    Participants who were symptom free for 24-hours were assessed with the help of a daily Dairy. It included the details on daily asthma symptom scores ranging from 0 (no symptoms) to 5-symptoms so severe that participant could not perform normal activity \[morning\] or to 4-symptoms so severe that participants could not sleep at all \[nightly\]. Mean change from Baseline was calculated as percentage of symptom free 24 hours during Period 2 (Week 9 to Week 20) minus Baseline. The Baseline value was the mean of the daily values in one week prior to randomization (Visit 5: Week 8). Adjusted mean change from baseline is presented \[least square mean (LSM)\].

    Time frame: From Week 9 to Week 20

  4. Least Squares Mean Change From Baseline in the Percentage of Rescue Free 24 Hour (hr) Periods During Period 2

    The time during which the participants did not have to take any rescue medication (medication intended to relieve symptoms immediately) was considered as a rescue free period. Participants who did not require inhalation of salbutamol (rescue medication) for 24-hours were captured with the help of a daily dairy, all participants were required to record use of rescue medication daily for day and night time separately on e-diary. Mean change from Baseline was calculated as percentage of rescue free 24 hour period during Period 2 (Week 9 to Week 20) minus Baseline value. The Baseline value was the mean of the daily values in one week prior to randomization (Visit 5: Week 8). Adjusted mean change from baseline is presented \[least square mean (LSM)\].

    Time frame: From Week 9 to Week 20

  5. Least Squares Mean Change From Baseline in Asthma Control Test (ACT) Score at the End of Period 2

    The total ACT score is the sum of the scores attributed to the five questions, ranging from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. An ACT score \>=20 indicates well-controlled asthma. The questions were designed to be self-completed by the participant. Mean change from Baseline was calculated as ACT score at the end of Period 2 (Week 20) minus Baseline value. The Baseline value was the predose value at randomization (Visit 5: Week 8). Adjusted mean change from baseline is presented \[least square mean(LSM)\].

    Time frame: Week 20

  6. Proportion of Subjects With ACT Score >= 20 at Visit 11 (Week 20)

    Asthma control test is a five item questionnaire with each response rating from 1 to 5 (1 is severe and 5 is no event) of asthma events over previous 4-weeks. The questions were designed to be self-completed by the participant. The percentage of participants with ACT score \>=20 at the end of the Period 2 were analyzed using a logistic regression model including covariates for baseline ACT score, gender, age and treatment group.

    Time frame: Week 20

07

Results

Posted Jun 20, 2016

Participant flow

A total of 551 participants were screened, 490 entered into the run-in period, 430 entered into the open label treatment period 1(Period 1) and 371 were further randomized to treatment Period 2 (Period 2). Note that 1 subject was randomized incorrectly even though the subject failed at randomization.

8 Weeks in Period 1
Participant flow — 8 Weeks in Period 1
MilestoneFF/VI 100/25 mcg ODFF 100 mcg ODFP 100 mcg BDFP 250 mcg BD
Started430000
Completed370000
Not completed60000
Withdrew: Adverse event9000
Withdrew: Lack of efficacy3000
Withdrew: Protocol violation2000
Withdrew: Protocol defined stopping criteria41000
Withdrew: Physician decision1000
Withdrew: Withdrawal by subject4000
12 Weeks in Period 2
Participant flow — 12 Weeks in Period 2
MilestoneFF/VI 100/25 mcg ODFF 100 mcg ODFP 100 mcg BDFP 250 mcg BD
Started0123124124
Completed0112112112
Not completed0111212
Withdrew: Adverse event0241
Withdrew: Lack of efficacy0100
Withdrew: Protocol defined stopping criteria05611
Withdrew: Withdrawal by subject0220
Withdrew: Randomized incorrectly0100

Outcome measures

PrimaryPercentage of Participants (Par) Withdrawn From the Study Due to "Poorly-controlled Asthma" During Period 2

Asthma symptom scores (SS) were recorded by par using ratings 0 (no symptoms) to 5-symptoms so severe that par could not perform normal activity \[morning\] or to 4-symptoms so severe that par could not sleep at all \[nightly\]. Withdrawal due to poorly-controlled(WPC) (required step-up therapy) asthma was defined as asthma worsening/exacerbation or ≧3 per week of : day symptoms on ≧ 2 days, rescue use on ≧2 days, morning PEF \<80 % of best effort on ≧ 1 day, night symptoms on ≧1 or more day, a best pre-bronchodilator forced expiratory volume in 1s (FEV1) \< 80% at clinic . Percentage of par WPC asthma at visit 6, 7, 9 and 11 (Week 10, 12, 16 and 20 respectively) were reported. Cox Proportional Hazards Model was used with covariates of Baseline FEV1, gender, age and treatment group. Analysis was descriptive only, no p -values calculated, treatment differences and associated 95% CI were produced.

Time frame:
From Week 9 to Week 20
Reported as:
Number · Percentage of Participants
Percentage of Participants (Par) Withdrawn From the Study Due to "Poorly-controlled Asthma" During Period 2
Percentage of ParticipantsFF 100 mcg ODFP 100 mcg BDFP 250 mcg BD
Percentage of Participants (Par) Withdrawn From the Study Due to "Poorly-controlled Asthma" During Period 24.9 (1.81 to 10.32)7.3 (3.37 to 13.33)8.1 (3.94 to 14.33)
Statistical analysis
  • FF 100 mcg OD vs FP 100 mcg BD · Hazard ratio (hr): 0.88 · 95% CI 0.31 to 2.49
  • FF 100 mcg OD vs FP 250 mcg BD · Hazard ratio (hr): 0.79 · 95% CI 0.28 to 2.19
PrimaryPercentage of Participants With 'Well-controlled Asthma' at the End of Period 2

Asthma symptom scores(SS) were recorded by par using ratings 0 (no symptoms) to 5-symptoms so severe that par could not perform normal activity\[morning\] or to 4-symptoms so severe that par could not sleep at all\[nightly\]. "Well-controlled asthma" was defined as having no exacerbation/asthma worsening, no night-time symptoms, a best pre-bronchodilator forced expiratory volume in 1 second ≥80% at clinic, and ≥2 per week of: daytime symptoms on ≤1 day, rescue use on ≤1 day, or morning peak expiratory flow ≥80% of the best effort value. "Well-controlled asthma" at the end of period 2 was assessed in the week prior to Visit 11 (Week 20). Percentage of participants were calculated as the number of participants with "well-controlled asthma" divided by total number participants excluding withdrawals prior to visit 11 (end of period 2) other than asthma worsening/exacerbation. A Logistic Regression Model was used with covariates of Baseline FEV1, gender, age and treatment group.

Time frame:
Week 20
Reported as:
Number · Percentage of Participants
Percentage of Participants With 'Well-controlled Asthma' at the End of Period 2
Percentage of ParticipantsFF 100 mcg ODFP 100 mcg BDFP 250 mcg BD
Percentage of Participants With 'Well-controlled Asthma' at the End of Period 289.5 (82.33 to 94.44)78.2 (69.65 to 85.20)83.1 (75.04 to 89.33)
Statistical analysis
  • FF 100 mcg OD vs FP 100 mcg BD · Odds ratio (or): 1.93 · 95% CI 0.90 to 4.12
  • FF 100 mcg OD vs FP 250 mcg BD · Odds ratio (or): 1.45 · 95% CI 0.66 to 3.20
SecondaryLeast Squares Mean Change From Baseline in Clinic Visit Trough FEV1 at the End of Period 2

FEV measures amount of air a person can exhale during a forced breath. The amount of air exhaled in one second of the forced breath is FEV1. Trough FEV1 was measured between 3pm and 11pm excluding Visit 1. Highest value from the three acceptable measurements were recorded. Change from Baseline was calculated as adjusted mean FEV1 value during Period 2 minus Baseline. The Baseline value was the predose value at the randomization (Visit 5: Week 8). Analysis of covariance (ANCOVA) Model was used with covariates of baseline FEV1, gender, age and treatment group. The adjusted mean from this model is presented \[least square mean (LSM)\].

Time frame:
Week 20
Reported as:
Least squares mean · Liter
Least Squares Mean Change From Baseline in Clinic Visit Trough FEV1 at the End of Period 2
LiterFF 100 mcg ODFP 100 mcg BDFP 250 mcg BD
Least Squares Mean Change From Baseline in Clinic Visit Trough FEV1 at the End of Period 2-0.129 ± 0.0158-0.135 ± 0.0154-0.105 ± 0.0155
SecondaryLeast Squares Mean Change From Baseline in Daily Morning (AM) and Evening (PM) PEF Averaged During Period 2

Peak expiratory flow is a person's maximum speed of expiration, as measured with a peak flow meter which determines person's ability to breathe out air. PEF was measured each morning and evening prior to study medication or any rescue salbutamol inhalation aerosol use, using an electronic peak flow meter. Mean change from Baseline was calculated as PEF value averaged during Period 2 (Week 9 to Week 20) minus Baseline. Data is presented separately for morning(AM) and evening(PM) assessments. The Baseline value was the mean of the daily values in one week prior to randomization (Visit 5: Week 8) separately for morning and evening. Adjusted mean change from baseline is presented \[least square mean (LSM)\].

Time frame:
From Week 9 to Week 20
Reported as:
Least squares mean · Liter per minute (L/min)
Least Squares Mean Change From Baseline in Daily Morning (AM) and Evening (PM) PEF Averaged During Period 2
Liter per minute (L/min)FF 100 mcg ODFP 100 mcg BDFP 250 mcg BD
PEF at AM, n=122, 124, 124-18.2 ± 2.09-21.3 ± 2.06-18.1 ± 2.06
PEF at PM, n=122, 124, 124-19.2 ± 2.04-19.3 ± 2.01-18.7 ± 2.02
SecondaryLeast Squares Mean Change From Baseline in the Percentage of Symptom Free 24 Hour Periods During Period 2

Participants who were symptom free for 24-hours were assessed with the help of a daily Dairy. It included the details on daily asthma symptom scores ranging from 0 (no symptoms) to 5-symptoms so severe that participant could not perform normal activity \[morning\] or to 4-symptoms so severe that participants could not sleep at all \[nightly\]. Mean change from Baseline was calculated as percentage of symptom free 24 hours during Period 2 (Week 9 to Week 20) minus Baseline. The Baseline value was the mean of the daily values in one week prior to randomization (Visit 5: Week 8). Adjusted mean change from baseline is presented \[least square mean (LSM)\].

Time frame:
From Week 9 to Week 20
Reported as:
Least squares mean · Percentage of symptom-free 24-h period
Least Squares Mean Change From Baseline in the Percentage of Symptom Free 24 Hour Periods During Period 2
Percentage of symptom-free 24-h periodFF 100 mcg ODFP 100 mcg BDFP 250 mcg BD
Least Squares Mean Change From Baseline in the Percentage of Symptom Free 24 Hour Periods During Period 2-1.0 ± 0.654-1.3 ± 0.653-1.8 ± 0.652
SecondaryLeast Squares Mean Change From Baseline in the Percentage of Rescue Free 24 Hour (hr) Periods During Period 2

The time during which the participants did not have to take any rescue medication (medication intended to relieve symptoms immediately) was considered as a rescue free period. Participants who did not require inhalation of salbutamol (rescue medication) for 24-hours were captured with the help of a daily dairy, all participants were required to record use of rescue medication daily for day and night time separately on e-diary. Mean change from Baseline was calculated as percentage of rescue free 24 hour period during Period 2 (Week 9 to Week 20) minus Baseline value. The Baseline value was the mean of the daily values in one week prior to randomization (Visit 5: Week 8). Adjusted mean change from baseline is presented \[least square mean (LSM)\].

Time frame:
From Week 9 to Week 20
Reported as:
Least squares mean · Percentage of rescue-free 24-hr periods
Least Squares Mean Change From Baseline in the Percentage of Rescue Free 24 Hour (hr) Periods During Period 2
Percentage of rescue-free 24-hr periodsFF 100 mcg ODFP 100 mcg BDFP 250 mcg BD
Least Squares Mean Change From Baseline in the Percentage of Rescue Free 24 Hour (hr) Periods During Period 2-0.9 ± 0.554-2.1 ± 0.553-1.2 ± 0.552
SecondaryLeast Squares Mean Change From Baseline in Asthma Control Test (ACT) Score at the End of Period 2

The total ACT score is the sum of the scores attributed to the five questions, ranging from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. An ACT score \>=20 indicates well-controlled asthma. The questions were designed to be self-completed by the participant. Mean change from Baseline was calculated as ACT score at the end of Period 2 (Week 20) minus Baseline value. The Baseline value was the predose value at randomization (Visit 5: Week 8). Adjusted mean change from baseline is presented \[least square mean(LSM)\].

Time frame:
Week 20
Reported as:
Least squares mean · Score on scale
Least Squares Mean Change From Baseline in Asthma Control Test (ACT) Score at the End of Period 2
Score on scaleFF 100 mcg ODFP 100 mcg BDFP 250 mcg BD
Least Squares Mean Change From Baseline in Asthma Control Test (ACT) Score at the End of Period 2-0.3 ± 0.225-0.6 ± 0.224-0.8 ± 0.223
SecondaryProportion of Subjects With ACT Score >= 20 at Visit 11 (Week 20)

Asthma control test is a five item questionnaire with each response rating from 1 to 5 (1 is severe and 5 is no event) of asthma events over previous 4-weeks. The questions were designed to be self-completed by the participant. The percentage of participants with ACT score \>=20 at the end of the Period 2 were analyzed using a logistic regression model including covariates for baseline ACT score, gender, age and treatment group.

Time frame:
Week 20
Reported as:
Number · Percentage of participants
Proportion of Subjects With ACT Score >= 20 at Visit 11 (Week 20)
Percentage of participantsFF 100 mcg ODFP 100 mcg BDFP 250 mcg BD
Proportion of Subjects With ACT Score >= 20 at Visit 11 (Week 20)99.1 (95.13 to 99.98)97.4 (92.50 to 99.45)96.5 (91.26 to 99.04)

Adverse events

Collected over Adverse events and Serious adverse events were collected from start of treatment Period 1 (Week 0) to Period 2 (Week 20).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF/VI 100/25 mcg OD Period 1—0/430 (0%)67/430 (15.6%)
FF 100 mcg OD Period 2—1/123 (0.8%)22/123 (17.9%)
FP 100 mcg BD Period 2—0/124 (0%)22/124 (17.7%)
FP 250 mcg BD Period 2—1/124 (0.8%)28/124 (22.6%)
Most frequent serious events
Most frequent serious events
EventFF/VI 100/25 mcg OD Period 1FF 100 mcg OD Period 2FP 100 mcg BD Period 2FP 250 mcg BD Period 2
Abortion completePregnancy, puerperium and perinatal conditions0/4301/1230/1240/124
Clavicle fractureInjury, poisoning and procedural complications0/4300/1230/1241/124
Most frequent other events
Most frequent other events
EventFF/VI 100/25 mcg OD Period 1FF 100 mcg OD Period 2FP 100 mcg BD Period 2FP 250 mcg BD Period 2
NasopharyngitisInfections and infestations67/43022/12322/12428/124

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Period 1- FF/VI 100/25 mcg OD
Mean48.1 ± 14.11
Sex: Female, Male
Sex: Female, Male(Participants)Period 1- FF/VI 100/25 mcg OD
Female261
Male169
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Period 1- FF/VI 100/25 mcg OD
Asian-Japanese Heritage430
08

Study locations

33 sites
  • GSK Investigational Site
    Aomori, 036-8545, Japan
  • GSK Investigational Site
    Fukuoka, 802-0052, Japan
  • GSK Investigational Site
    Fukuoka, 811-1394, Japan
  • GSK Investigational Site
    Fukuoka, 816-0813, Japan
  • GSK Investigational Site
    Fukuoka, 832-0059, Japan
  • GSK Investigational Site
    Gifu, 509-6134, Japan
  • GSK Investigational Site
    Hiroshima, 732-0052, Japan
  • GSK Investigational Site
    Hyogo, 672-8064, Japan
  • GSK Investigational Site
    Ibaraki, 302-0022, Japan
  • GSK Investigational Site
    Ibaraki, 319-1113, Japan
  • GSK Investigational Site
    Kagawa, 760-0018, Japan
  • GSK Investigational Site
    Kagawa, 760-8538, Japan
  • GSK Investigational Site
    Kagawa, 761-8073, Japan
  • GSK Investigational Site
    Kagawa, 762-0031, Japan
  • GSK Investigational Site
    Kanagawa, 239-0821, Japan
  • GSK Investigational Site
    Kanagawa, 252-0143, Japan
  • GSK Investigational Site
    Kochi, 780-0901, Japan
  • GSK Investigational Site
    Kyoto, 612-0026, Japan
  • GSK Investigational Site
    Mie, 514-1101, Japan
  • GSK Investigational Site
    Mie, 515-8544, Japan
  • GSK Investigational Site
    Oita, 870-0921, Japan
  • GSK Investigational Site
    Osaka, 560-0005, Japan
  • GSK Investigational Site
    Saitama, 343-0808, Japan
  • GSK Investigational Site
    Tokyo, 103-0027, Japan
  • GSK Investigational Site
    Tokyo, 104-8560, Japan
  • GSK Investigational Site
    Tokyo, 140-0011, Japan
  • GSK Investigational Site
    Tokyo, 140-0013, Japan
  • GSK Investigational Site
    Tokyo, 145-0063, Japan
  • GSK Investigational Site
    Tokyo, 171-0014, Japan
  • GSK Investigational Site
    Tokyo, 187-0002, Japan
  • GSK Investigational Site
    Tokyo, 190-0014, Japan
  • GSK Investigational Site
    Tokyo, 191-0031, Japan
  • GSK Investigational Site
    Tokyo, 204-8522, Japan
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Aug 2015, 17 months.

Results were first posted in Jun 2016, 9 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 17 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2014
First posted
Mar 24, 2014
StartActual
Mar 27, 2014
Primary completionActual
Aug 28, 2015
CompletionActual
Aug 28, 2015
Results first posted
Jun 20, 2016
Last update
May 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02094937
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 24, 2014
Start date
Mar 27, 2014
Primary completion
Aug 28, 2015
Completion
Aug 28, 2015
Results posted
Jun 20, 2016
Last update
May 25, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol · Fluticasone

Start the discussion